Diatherix Laboratories, Inc. (DLI) provides clinical laboratory services on a multiplexing platform for the detection of infectious diseases. The testing is based upon molecular differential diagnostics (MDD) for the identification of DNA/RNA for bacteria and viruses. The primary area of focus in infectious disease includes pathogens associated with respiratory infections, Staphylococcus differentiation including MRSA and healthcare associated infections (HAI).
DLI has developed a high complexity CLIA certified clinical laboratory to provide services to its target market customers. This service provides testing to clients that need the results but cannot afford the capital investment for an instrument or the products. In this way, the client gains access to DLI’s unique infectious disease services, as well as, information regarding infectious disease detection and drug resistance. Further, this service provides surveillance for hospitals in support of their infection prevention and control programs for the reduction of isolation days and the reduction of unnecessary antibiotic use for colonized patients. This places Diatherix in a position to develop unique multiplex panels that are disease specific and partnerships with hospitals as it brings its knowledge as a thought leader in infectious disease innovation to healthcare.